Evidence map›Paper›PMID 29376902›Full record

ReviewJournal of fungi (Basel, Switzerland)2015

Efinaconazole Topical Solution, 10%: Factors Contributing to Onychomycosis Success.

Richard A Pollak, William J Jo Siu, Yoshiyuki Tatsumi, Radhakrishnan Pillai

Abstract readReview
In one paragraph

Review in Journal of fungi (Basel, Switzerland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Dermatophytomas: Clinical Overview and Treatment.Journal of fungi (Basel, Switzerland) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Richard A PollakSan Antonio Podiatry Associates, San Antonio, TX 78229, USA. drrichardpollak@gmail.com.
William J Jo SiuDow Pharmaceutical Sciences, a Division of Valeant Pharmaceuticals North America LLC, Petaluma, CA 94954, USA. wjo@dowpharmsci.com.
Yoshiyuki TatsumiKaken Pharmaceutical Co. Ltd., Kyoto 607-8042, Japan. tatsumi_yoshiyuki@kaken.co.jp.
Radhakrishnan PillaiDow Pharmaceutical Sciences, a Division of Valeant Pharmaceuticals North America LLC, Petaluma, CA 94954, USA. RPillai@dowpharmsci.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To provide an adequate therapeutic effect against onychomycosis, it has been suggested that topical drugs should have two properties: drug permeability through the nail plate and into the nail bed, and retention of their antifungal activity in the disease-affected areas. Only recently has the importance of other delivery routes (such as subungual) been discussed. Efinaconazole has been shown to have a more potent antifungal activity

Indexed as

efinaconazolefungionychomycosistoenailtopical therapy

Identifiers

PMID29376902
PMCPMC5753103

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.